小児急性脳炎・脳症のとらえ方と治療戦略

出版社： 中山書店
著者：
発行日： 2022-06-20
分野： 臨床医学：内科  >  小児科学一般
ISBN： 9784521749235
電子書籍版： 2022-06-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,680 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

9,680 円(税込)

購入する

商品紹介

日本がリーダーシップをとり，常に牽引しつづけている小児急性脳炎・脳症．
ガイドラインをさらに踏み込んだエキスパートコンセンサスが蓄積され，研究・臨床の最新知見，有効性を示す症例を収載．さまざまな疾患・病態に起因し診断が難しい急性脳症の要点を「診断のポイント」で解説，難治性が多く家族への伝え方が難しい「家族への説明」を語り口調で紹介．

目次

  • Appendix　1　急性脳症の見つけ方・見分け方
    Appendix　2　症候群分類

    1章　急性脳症概論
    　急性脳症の概念・定義・分類
    　感染病原体と急性脳症臨床病型との関連
    　急性脳症の疫学・予後
    　急性脳症の病因・病態
    　急性脳炎・急性脳症の神経病理

    2章　急性脳症の検査・診断
    　急性脳症の診断・検査・鑑別診断
    　頭部画像検査
    　脳波検査
    　脳波モニタリング
    　熱性けいれん重積と急性脳症の鑑別

    3章　急性脳症の治療
    　てんかん重積状態の治療
    　急性期全身管理・支持療法
    　脳低温療法・脳平温療法
    　急性脳症の特異的治療
    　けいれん重積後の急性脳症予防・早期治療プロトコール例（1）鳥取大学
    　けいれん重積後の急性脳症予防・早期治療プロトコール例（2）兵庫県立こども病院
    　後遺症とリハビリテーション

    4章　急性脳炎・急性脳症の臨床
    　けいれん重積型（二相性）急性脳症（AESD）
    　可逆性脳梁膨大部病変を有する軽症脳炎・脳症（MERS）
    　出血性ショック脳症症候群（HSES）
    　急性壊死性脳症（ANE）
    　難治頻回部分発作重積型急性脳炎（AERRPS）
    　Reye症候群・Reye様症候群
    　インフルエンザ脳症
    　突発性発疹（HHV-6,7）脳炎・脳症
    　単純ヘルペス脳炎
    　マイコプラズマ感染症に伴う脳炎
    　サイトメガロウイルス中枢神経感染症
    　急性弛緩性脊髄炎
    　先天代謝異常症による急性脳症
    　Dravet症候群に合併する急性脳症
    　急性脳症を合併しやすい慢性基礎疾患
    　急性疾患に合併・併発する急性脳症
    　抗NMDA受容体脳炎
    　自己免疫性脳症－急性散在性脳脊髄炎，オプソクローヌス・ミオクローヌス症候群
    　可逆性後部白質脳症（PRES）
    　急性小脳失調症

    略語一覧

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 急性脳症概論

P.8 掲載の参考文献
1) Krupp B, et al. Consensus definitions for pediatric multiple sclerosis and related disorders. Neurology 2007 ; 68 : S7-12.
 
2) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016. p. 2-6.
 
3) Mizuguchi M, et al. Guidelines for the diagnosis and treatment of acute encephalopathy in childhood. Brain Dev 2021 ; 43 : 2-31.
PubMed
4) Mizuguchi M, et al. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand 2007 ; 115 : 45-56.
PubMed
5) Kasai M, et al. Epidemiological changes or acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
 
6) Shibata A, et al. Thermolabile polymorphism of carnitine palmitoyltransferase 2 : a genetic factor for overall acute encephalopathy. Brain Dev 2019 ; 41 : 862-9.
PubMed
P.14 掲載の参考文献
1) Hoshino A, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev 2012 ; 34 : 337-43.
PubMed
2) Kasai M, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
PubMed
3) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
P.20 掲載の参考文献
1) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
2)Kasai M, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
PubMed
3) 厚生労働科学研究費補助金 難治性疾患政策研究事業 良質なエビデンスに基づく急性脳症の診療に向けた体制整備 : 平成30年度研究報告書 急性脳症の全国実態調査 (第2回, 平成29年度実施), http://www.development.m.u-tokyo.ac.jp/Acute%20Encephalopathy/20190329/Acute%20encephalopathy_2nd%20surveryR.pdr (最終閲覧 2021年10月)
 
4) Hoshino A, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev 2012 ; 34 : 337-43.
PubMed
5) 厚生労働科学研究費補助金 難治性疾患克服研究事業 重症・難治性急性脳症の病因解明と診療確立に向けた研究 : 平成22年度研究報告書 急性脳症の全国実態調査. http://www.development.m.u-tokyo.ac.jp/Acute%20Encephalopathy/H22_AcuteEncephalopathy.pdf (最終閲覧 2021年10月)
 
P.26 掲載の参考文献
1) Saitoh M, et al. Clinical and genetic features of acute encephalopathy in children taking theophylline. Brain Dev 2015 ; 37 : 463-70. doi : 10.1016/j.braindev.2014.07.010.
 
2) Casteels-Van Daele M, et al. Reye syndrome revisited : a descriptive term covering a group of heterogeneous disorders. Eur J Pediatr 2000 ; 159 : 641-8. doi : 10.1007/PL00008399.
 
3) Gosalakkal JA, Kamoji V. Reye syndrome and Reye-like syndrome. Pediatr Neurol 2008 ; 39 : 198-200. doi : 10.1016/j.pediatrneurol.2008.06.003.
 
4) Corti S, et al. et al. Clinical reatures and new molecular findings in carnitine palmitoyltransferase II (CPT II) deficiency. J Neurol Sci 2008 ; 266 : 97-103. doi : 10.1016/j.jns.2007.09.015.
 
5) Bonnefont JP, et al. Carnitine palmitoyltransferase deficiencies. Mol Genet Metab 1999 ; 68 : 424-40. doi : 10.1006/mgme.1999.2938.
 
6) Joshi PR, et al. Carnitine palmitoyltransferase II (CPT II) deficiency : genotype-phenotype analysis of 50 patients. J Neurol Sci 2014 ; 338 : 107-11. doi : 10.1016/j.jns.2013.12.026.
 
7) Shibata A, et al. Thermolabile polymorphism of carnitine palmitoyltransferase 2 : a genetic risk factor of overall acute encephalopathy. Brain Dev 2019 ; 41 : 862-9. doi : 10.1016/j.braindev.2019.07.008.
 
8) Shinohara M, et al. Carnitine palmitoyl transferase II polymorphism is associated with multiple syndromes of acute encephalopathy with various infectious diseases. Brain Dev 2011 ; 33 : 512-7. doi : 10.1016/j.braindev.2010.09.002.
 
9) Chen Y, et al. Thermolabile phenotype of carnitine palmitoyltransferase II variations as a predisposing factor for influenza-associated encephalopathy. FEBS Len 2005 ; 579 : 2040-4. doi : 10.1016/j.febslet.2005.02.050.
 
10) Kubota M, et al. Thermolabile CPT II variants and low blood ATP levels are closely related to severity of acute encephalopathy in Japanese children. Brain Dev 2012 ; 34 : 20-7. doi : 10.1016/j.braindev.2010.12.012.
 
11) Yao D, et al. Thermal instability of compound variants of carnitine palmitoyltransferase II and impaired mitochondrial fuel utilization in influenza-associated encephalopathy. Hum Mutat 2008 ; 29 : 718-27. doi : 10.1002/humu.20717.
 
12) Shinohara M, et al. ADORA2A polymorphism predisposes children to encephalopathy with febrile status epilepticus. Neurology 2013 ; 80 : 1571-6. doi : 10.1212/WNL.0b013e31828fl8d8.
 
13) Hoshino A, et al. Specific HLA genotypes confer susceptibility to acute necrotizing encephalopathy. Genes Immun 2016 ; 17 : 367-9. doi : 10.1038/gene.2016.32.
 
14) Okumura A, et al. Acute encephalopathy in children with Dravet syndrome. Epilepsia 2012 ; 53 : 79-86. doi : 10.1111/j.1528-1167.2011.03311.x.
 
15) Sakauchi M, et al. Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia 2011 ; 52 : 1144-9. doi : 10.1111/j.1528-1167.2011.03053.x.
 
16) Dravet C. Acute encephalopathy after febrile status epilepticus : an underdiagnosed, misunderstood complication of Dravet syndrome. Dev Med Child Neurol 2018 ; 60 : 534. doi : 10.1111/dmcn.13778.
 
17) Saitoh M, et al. Mutations of the SCN1A gene in acute encephalopathy. Epilepsia 2012 ; 53 : 558-64. doi : 10.1111/j.1528-1167.2011.03402.x.
 
18) Kobayashi K, et al. Genetic seizure susceptibility underlying acute encephalopathies in childhood. Epilepsy Res 2010 ; 91 : 143-52. doi : 10.1016/j.eplepsyres.2010.07.005.
 
19) Saitoh M, et al. Cytokine-related and sodium channel polymorphism as candidate predisposing factors for childhood encephalopathy FIRES/AERRPS. J Neurol Sci 2016 ; 368 : 272-6. doi : 10.1016/j.jns.2016.07.040.
 
20) Kobayashi K, et al. Acute encephalopathy with a novel point mutation in the SCN2A gene. Epilepsy Res 2012 ; 102 : 109-12. doi : 10.1016/j.eplepsyres.2012.04.016.
 
21) Saitoh M, et al. Missense mutations in sodium channel SCN1A and SCN2A predispose children to encephalopathy with severe febrile seizures. Epilepsy Res 2015 ; 117 : 1-6. doi : 10.1016/j.eplepsyres.2015.08.001.
 
22) Numoto S, et al. Acute encephalopathy in children with tuberous sclerosis complex. Orphanet J Rare Dis 2021 ; 16 : 1-9. doi : 10.1186/s13023-020-01646-8.
 
23) Shibata A, et al. Case-control association study of rare nonsynonymous variants or SCN1A and KCNQ2 in acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2020 ; 414 : 116808. doi : 10.1016/j.jns.2020.116808.
PubMed
24) Yamazaki S, et al. Hemiconvulsion-hemiplegia-epilepsy syndrome associated with CACNA1A S218L mutation. Pediatr Neurol 2011 ; 45 : 193-6. doi : 10.1016/j.pediatrneurol.2011.04.010.
 
25) Belal H, et al. De novo variants in RHOBTB2, an atypical Rho GTPase gene, cause epileptic encephalopathy. Hum Mutat 2018 ; 39 : 1070-5. doi : 10.1002/humu.23550.
 
26) Shimada S, et al. An episode of acute encephalopathy with biphasic seizures and late reduced diffusion followed by hemiplegia and intractable epilepsy observed in a patient with a novel frameshift mutation in HNRNPU. Brain Dev 2018 ; 40 : 813-8. doi : 10.1016/j.braindev.2018.05.010.
 
27) Ohashi E, et al. Recurrent acute necrotizing encephalopathy in a boy with RANBP2 mutation and thermolabile CPT2 variant : The first case of ANE1 in Japan. Brain Dev 2021 ; 43 : 873-8. doi : 10.1016/j.braindev.2021.04.009.
 
28) Kurahashi H, et al. MYRF is associated with encephalopathy with reversible myelin vacuolization. Ann Neurol 2018 ; 83 : 98-106. doi : 10.1002/ana.25125.
 
29) 竹丸誠ほか. 一過性の繰り返す大脳白質病変を示し, GJB1遺伝子点変異ヘテロ接合体のX連鎖Charcot-Marie-Tooth病の女性例. 臨床神経学 2018 ; 58 : 302-7.
 
P.32 掲載の参考文献
1) 林雅晴. 脳炎・脳症・髄膜炎の病理所見からわかること. 小児内科 2013 ; 45 : 191-4.
Medical*Online
2) 小池智. エンテロウイルス71受容体SCARB2の同定. ウイルス 2008 ; 59 : 189-94.
 
3) Mizuguchi M, et al. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand 2007 ; 115 : 45-56.
PubMed
4) Sellers SA, et al. The hidden burden of influenza : a review of the extra-pulmonary complications or influenza infections. Influenza Other Respir Viruses 2017 ; 11 : 372-93.
PubMed
5) 河島尚志ほか. 小児感染免疫疾患の病理-インフルエンザ脳症. 病理と臨床 2008 ; 26 : 904-9.
Medical*Online
6) 大浜栄作. アストロサイトの解剖学と病理学. Clinical Neuroscience 2011 ; 29 : 1228-33.
 
7) Tachibana M, et al. Clasmatodendrosis is associated with dendritic spines and does not represent autophagic astrocyte death in influenza-associated encephalopathy. Brain Dev 2019 ; 41 : 85-95.
 
8) Ryu HJ, et al. p65/RelA-Ser529 NF-kappa B subunit phosphorylation induces autophagic astroglial death (Clasmatodendrosis) following status epilepticus. Cell Mol Neurobiol 2011 ; 31 : 1071-8.
PubMed
9) Shimoda K, et al. Brain edema with clasmatodendrosis complicating ataxia telangiectasia. Brain Dev 2017 ; 39 : 629-32.
PubMed
10) Hayashi M, et al. Pathological examination of influenza virus-associated and autoimmune encephalitis/encephalopathy in children. In : Vuliagione JM, et al. eds. Pathology : New Research. New York : Nova Science Publishers ; 2012. p. 73-89.
 
11) Fujita Y, et al. Activated microglia in acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2016 ; 366 : 91-3.
PubMed
12) Takanashi J, et al. Loss of myelinated axons and alopathy with biphasic seizures and late reduced diffusion.Brain Dev 2018 ; 40 : 947-51.
 
13) Nakajima K, et al. Glial fibrillary acidic protein and S100 calcium-binding protein B in the cerebrospinal fluid or children with acute neurological disorders. In : Kahr C, et al. eds. Glial Cells : Embryonic Development Types/Functions and Role in Diseasc. New York : Nova Science Publishers ; 2013. p. 108-16.
 
14) 林雅晴. 脳発達障害と酸化ストレス. 日児誌 2009 ; 113 : 657-66.
 
15) Hayashi M, et al. Neurodegenerative mechanisms in subacute sclerosing panencephalitis. J Child Neurol 2002 ; 17 : 725-30.
PubMed

2章 急性脳症の検査・診断

P.41 掲載の参考文献
1) 日本小児神経学会監. 小児急性脳症診療ガイドラン策定委員会編. 小児急性脳症診療ガイドラン 2016. 東京 : 診断と治療社 ; 2016.
 
2) Mizuguchi M, et al. Guidelines for the diagnosis and treatment of acute encephalopathy in childhood. Brain Dev 2021 ; 43 : 2-31.
PubMed
3) 井上岳司. 急性脳症-小児神経救急臨床からのアプローチ. 日小児救急医会誌 2020 ; 19 : 171-80.
 
4) 奥村彰久. 小児急性脳症診療ガイドラインのポイント. 脳と発達 2019 : 51 : 159-61.
Medical*Online
5) 日本小児神経学会. インフルエンザ脳症の診療戦略. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf (最終閲覧 2021年10月)
 
6) 林下浩士ほか. 脳腫脹が進行する急性症の早期診断指標 代謝性アシドースが2時間持続する症例は熱性痙攣でない. 日小児救急医会誌 2011 ; 10 : 9-13.
 
7) 塩見正司. ウイルス感染症 中枢神経系疾患 インフルエザ脳症. 日本臨床 2003 ; 61 : 100-6.
 
8) Neilson DE, et al. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet 2009 ; 84 : 44-51.
 
9) Saitoh M, et al. Missense mutations in sodium channel SCN1A and SCN2A predispose children to encephalopathy with severe febrile seizures. Epilepsy Res 2015 ; 117 : 1-6.
PubMed
10) Shinohara M, et al. ADORA2A polymorphism predisposes children to encephalopathy with fevrile status epilepticus. Neurology 2013 ; 80 : 1571-6.
 
11) Ichiyama T, et al. Serum and cerebrospinal fluid levels of cytokines in acute encephalopathy associated with human herpesvirus-6 infection. Brain Dev 2009 ; 31 : 731-8.
PubMed
12) Cellucci T, et al. Clinical approach to the diagnosis of autoimmune encephalitls in the pediatric patient. Neurol Neuroimmunol Neuroinflamm 2020 ; 7 : e663.
 
13) Akiyama T, et al. Vitamin B6 in acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2020 ; 42 : 402-7.
PubMed
14) Takanashi JI, et al. Prognostic value of MR spectrscoppy in patients with acute excitotoxic encephalopathy. J Neurol Sci 2020 ; 408 : 116636.
PubMed
15) Uetani H, et al. Perfusion abnormality on three-dimensional arterial spin labeling in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2020 ; 408 : 116558.
PubMed
16) Shetty R, et al. Cerebral perfusion pressur-targeted approach in children with central nervous system infections and raised intracranial pressure : is it feasible? J Child Neurol 2008 ; 23 : 192-8.
 
17) 林下浩士ほか. 持続脳圧センサーによるインフルエンザ脳症の管理経験. 日集中医誌 2004 ; 11 : 237-41.
 
18) Covanis A, Panayiotopound syndrome : a benign childhood autonomic epilepsy frequently imitating encephalitis, syncope, migraine, sleep disorder, or gastroenteritis. Pediatrics 2006 ; 118 : e1237-43.
PubMed
P.49 掲載の参考文献
1) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
2) 日本医療研究開発機構研究費「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.ip/uploads/files/about/influenzaencephalopathy2018.pdf
 
3) 木村清次ほか. 感染に伴う急性脳症35例の臨床的検討. 脳と発達 1998 ; 30 : 244-9.
Medical*Online
4) 高梨潤一. 急性脳炎・脳症. 小児科診療 2018 ; 81 : 1049-57.
Medical*Online
5) 前垣義弘. 出血性ショック脳症症候群. 日本臨床 2011 ; 69 : 460-4.
Medical*Online
6) Uetani H, et al. Perfusion abnormality on three-dimensional arterial spin labeling in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2020 ; 408 : 116558.
PubMed
7) Imamura T, et al. Sisters with clinically mild encephalopathy with a reversible splenial lesion (MERS) -like features ; familial MERS? J Neurol Sci 2010 ; 290 : 153-6.
 
8) Kurahashi H, et al. MYRF is associated with encephalopathy with reversible myelin vacuolization. Ann Neurol 2018 ; 83 : 98-106.
PubMed
P.58 掲載の参考文献
1) Gloor P, et al. Brain lesions that produce delta waves in the EEG. Neurology 1977 ; 27 : 326-33.
PubMed
2) 松浦雅人. 臨床神経生理検査の実際. 東京 : 新興医学出版社 ; 2007. p. 49-51.
 
3) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016. p. 30-7.
 
4) 井上岳司ほか. 当院救急外来でペーパレス脳波を施行した症例の臨床的検討. 脳と発達 2012 ; 44 : 305-9.
Medical*Online
5) Maegaki Y, et al. Clinical characteristics of acute encephalopathy of obscure origin : a biphasic clinical course is a common feature. Neuropediatrics 2006 ; 37 : 269-77.
PubMed
6) Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev 2009 ; 31 : 521-8.
PubMed
7) Takanashi J, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006 ; 66 : 1304-9 ; discussion 291.
 
8) 吉野智美ほか. 頭部外傷後にけいれん重積型急性脳症 (AESD) と類似する経過を呈した虐待による頭部外傷 (AHT) 疑いの2乳児例. 日小児救急医会誌 2021 ; 20 : 43-7.
 
9) 夏目淳ほか. 特集「脳波が主役 : 意識障害・神経救急の診断学」小児の急性脳症, 熱性けいれん重積における脳波. 臨床神径生理学 2019 ; 47 : 53-7.
 
10) Nordli DR, et al. The role of EEG in febrile status epilepticus (FSE). Brain Dev 2010 ; 32 : 37-41.
PubMed
11) 龍神布紀子ほか. 熱性けいれん重積状態後の脳波の特徴. 脳と発達 2015 ; 47 : 14-6.
Medical*Online
12) Oguri M, et al. Distinguishing acute encephalopathy with biphasic seizures and late reduced diffusion from prolonged febrile seizures by acute phase EEG spectrum analysis. Yonago Acta Med 2016 ; 59 : 1-14.
PubMed
13) Ohno A, et al. Acute encephalopathy with biphasic seizures and late reduced diffusion : Predictive EEG findings. Brain Dev 2021 ; Dec 4 : S0387-7604 (21) 00208-4.
 
14) Hashimoto Y, et al. A splenial lesion with transiently reduced diffusion in clinically mild encephalitis is not always reversible : a case report. Brain Dev 2009 ; 31 : 710-2.
 
15) Mizuguchi M, et al. Acute necrotising encephalopathy of childhood : a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry 1995 ; 58 : 555-61.
PubMed
16) Thebaud B, et al. Haemorrhagjc shock and encephalopathy syndrome : neurological course and predictors of outcome. Intensive Care Med 1999 ; 25 : 293-9.
PubMed
17) Harden A, et al. EEG features and their evolution in the acute phase of haemorrhagic shock and encephalopathy syndrome. Neuropediatrics 1991 ; 22 : 194-7.
PubMed
18) Okumura A, et al. Amplitude-integrated electroencephalography in patients with acute encephalopathy with refractory, repetitive partial seizures. Brain Dev 2011 ; 33 : 77-82.
PubMed
19) Bitnun A, et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin Infect Dis 2001 ; 32 : 1674-84.
PubMed
20) Walsh JM, et al. Periodic lateralized epileptiform discharges-long-term outcome in adults. Epilepsia 1987 ; 28 : 533-6.
PubMed
21) de la Paz D, et al. Bilateral independent periodic lateralized epileptiform discharges. Clinical significance. Arch Neurol 1981 ; 38 : 713-5.
PubMed
22) 奥村彰久. 急性脳症の診療・研究最前線-急性脳症における脳波. 脳と発達 2011 ; 43 : 110-6.
 
23) Freilich ER, et al. Pediatric status epilepticus : identification and evaluation. Curr Opin Pediatr 2014 ; 26 : 655-61.
PubMed
24) Schreiber JM, et al. Continuous video EEG for patients with acute encephalopathy in a pediatric intensive care unit. Neurocrit Care 2012 ; 17 : 31-8.
 
P.68 掲載の参考文献
1) Scheuer ML. Continuous EEG monitoring in the intensive care unit. Epilepsia 2002 ; 43 Suppl 3 : 114-27.
 
2) Wartenberg KE, Mayer SA. Multimodal brain monitoring in the neurological intensive care unit : where does continuous EEG fit in? J Clin Neurophysiol 2005 ; 22 : 124-7.
 
3) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
4) McCoy B, et al. Predictors of nonconvulsive seizures among critically ill children. Epilepsia 2011 ; 52 : 1973-8.
PubMed
5) Abend NS, et al. Nonconvulsive seizures are common in critically ill children. Neurology 2011 ; 76 : 1071-7.
PubMed
6) Payne ET, et al. Seizure burden is independently associated with short term outcome in critically ill children. Brain 2014 ; 137 : 1429-38.
PubMed
7) Maruyama A, et al. Early non-convulsive seizures are associated with the development of acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2021 ; 43 : 548-55.
PubMed
8) Wagenman KL, et al. Electrographic status epilepticus and long-term outcome in critically ill children. Neurology 2014 ; 82 : 396-404.
PubMed
9) Bozarth XL, et al. Current status of continuous electroencephalographic monitoring in critically Ill children. Pediatr Neurol 2019 ; 101 : 11-7.
PubMed
10) You W, et al. Amplitude-integrated electroen-cephalography predicts outcome in patients with coma after acute brain injury. Neurosci Bull 2018 ; 34 : 639-46.
 
11) Ghassemi MM, et al. Quantitative electroencephalogram trends predict recovery in hypoxic-ischemic encephalopathy. Crit Care Med 2019 ; 47 : 1416-23.
PubMed
12) Kidokoro H, et al. Neonatal seizure identification on reduced channel EEG. Arch Dis Child Fetal Neonatal Ed 2013 ; 98 : F359-61.
PubMed
13) Chau DF, et al. The effectiveness of an interdisciplinary approach to EBG instruction for residents (r), J Clin Neurophysiol 2010 ; 27 : 106-9.
 
14) Shah DK, et al. Amplitude-integrated electroencephalography in the newborn : a valuable tool. Pediatrics 2008 ; 122 : 863-5.
PubMed
15) Salinsky M, et al. Representation of sleep stages by color density spectral array. Electroencephalogr Clin Neurophysiol 1987 ; 60 : 579-82.
 
16) Scheuer ML, Wilson SB. Data analysis for continuous EEG monitoring in the ICU : seeing the forest and the trees. J Clin Neurophysiol 2004 ; 21 : 353-78.
 
17) Stewart CP, et al. Seizure identification in the ICU using quantitative EEG displays. Neurology 2010 ; 75 : 1501-8.
PubMed
P.75 掲載の参考文献
1) Subcommittee on Febrile Seizures ; American Academy of Pediatrics. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics 2011 ; 127 : 389-94.
 
2) Tsuboi T. Epidemiology of febrile and afebrile convulsions in children in Japan. Neurology 1984 ; 34 : 175-81.
PubMed
3) Nishiyama M, et al. Seizure prevalence in children aged up to 3 years : a longitudinal population-based cohort stydy in Japan. BMJ Open 2020 : 10 : e035977.
 
4) Nishiyama I, et al. An epidemiological study of children with status epilepticus in Okayama, Japan : incidence, etiologies, and outcomes. Epilepsy Res 2011 ; 96 : 89-95.
PubMed
5) Verity CM, et al. Long-term intellectual and behavioral outcomes of children with febrile convulsions. N Engl J Med 1998 ; 338 : 1723-8.
PubMed
6) Mizuguchi M, et al. Guidelines for the diagnosis and treatment of acute encephalopathy in childhood. Brain Dev 2021 ; 43 : 2-31.
PubMed
7) Raspall-Chaure M, et al. Outcome of paediatric convulsive status epilepticus : a systematic review. Lancet Neurol 2006 ; 5 : 769-79.
PubMed
8) Tada H, et al. Predicitive score for early diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion (AESD). J Neurol Sci 2015 ; 358 : 62-5.
 
9) Hirayama Y, et al. "Symptomatic" infection-associated acute encephalopathy in children with underlying neurological disorders. Brain Dev 2017 ; 39 : 243-7.
PubMed
10) Nishiyama M, et al. Demographics and outcomes of patients with pediatric febrile convulsive status epilepticus. Pediatr Neurol 2015 ; 52 : 499-503.
PubMed
11) Maegaki Y, et al. Risk factors for fatality and neurological sequelae after status epilepticus in children. Neuropediatrics 2005 ; 36 : 186-92.
PubMed
12) Yokochi T, et al. Prediction or acute encephalopathy with biphasic seizures and late reduced diffusion in patients with febrile status epilepticus. Brain Dev 2016 ; 38 : 217-24.
 
13) 永瀬裕朗ほか. 複雑型熱性けいれんの予後不良因子を用いた急性脳症治療開始基準の検討. 日児誌 2010 ; 114 : 858-64.
 
14) Kuki I, et al. Characteristic neuroradiologic features in hemorrhagic shock and encephalopathy syndrome. J Child Neurol 2015 ; 30 : 468-75.
PubMed
15) 井上岳司ほか. 当院救急外来でペーパレス脳波を施行した症例の臨床的検討. 脳と発達 2012 ; 44 : 305-9.
Medical*Online
16) Oguri M, et al. Distinguishing acute encephalopathy with biphasic seizures and late reduced diffusion from prolonged febrile seizures by acute phase EEG spectrum analysis. Yonago Acta Med 2016 ; 59 : 1-14.
PubMed
17) Maruyama A, et al. Early non-convulsive seizures are associated with the development of acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2021 ; 43 : 548-55.
PubMed
18) 市坂有ほか. 二相性脳症における早期治療介入基準についての比較検討及びその活用. 日小児救急医会誌 2018 ; 17 : 396-400.
 
19) Nishiyama M, et al. Prediction of AESD and neurological sequelae in febrile status epilepticus. Brain Dev 2021 ; 43 : 616-25.
PubMed
20) Edwards AD, et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy : synthesis and meta-analysis of trial data. BMJ 2010 ; 340 : c363.
PubMed
21) 岩田欧介ほか. 脳保護という幻想を現実に. 日児誌 2009 ; 113 : 909-22.
 
22) Group THaCAS. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002 ; 346 : 549-56.
 
23) Shankaran S, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 2005 ; 353 : 1574-84.
PubMed
24) Hemmen TM, et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L) : final results. Stroke 2010 ; 41 : 2265-70.
PubMed
25) Hutchison JS, et al. Hypothermia therapy after traumatic brain injury in children. N Engl J Med 2008 ; 358 : 2447-56.
PubMed
26) Legriel S, et al. Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med 2016 ; 375 : 2457-67.
PubMed
27) Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus : a critical review of available therapies and a clinical treatment protocol. Brain 2011 ; 134 : 2802-18.
 

3章 急性脳症の治療

P.84 掲載の参考文献
1) Commission on epidemiology and prognosis, International League Against Epilepsy, Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993 ; 34 : 592-6.
PubMed
2) Lowenstein DH, et al. It's time to revise the definition of status epilepticus. Epilepsia 1999 ; 40 : 120-2.
 
3) Trinka E, et al. A definition and classification of status epilepticus : Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015 ; 56 : 1515-23.
PubMed
4) 菊池健二郎. てんかん重積状態 (けいれん重積状態) のup to date. 日本小児救急医会誌 2020 : 19 : 149-59.
 
5) Moretti R, et al. Buccal midazolam compared with rectal diazepam reduces seizure duration in children in the outpatient setting. Pediatr Emer Care 2019 ; 35 : 760-4.
 
6) Anderson M. Buccal midazolam for pediatric convulsive seizures : efficacy, safety, and patient acceptability. Patient Prefer Adherence 2013 ; 7 : 27-34.
PubMed
7) Yoshinaga H, et al. A Phase 3 open-label study of the efficacy, safety and pharmacokinetics of buccally administered midazolam hydrochloride for the treatment of status epilepticus in pediatric Japanese subjects. Epilepsy Res 2021 ; 174 : 106651.
PubMed
8) 日本小児神経学会監. 小児けいれん重積治療ガイドライン策定ワーキンググループ編. 小児けいれん重積治療ガイドライン 2017. 東京 : 診断と治療社 ; 2017. p. 24-32.
 
9) 菊池健二郎ほか. てんかん重積状態 (けいれん重積状態) の治療-最近の変化. 日児誌 2021 ; 125 : 557-68.
 
10) 菊池健二郎ほか. 小児けいれん重積治療ガイドライン発刊後の治療薬選択の現状と改訂の要望. 日児誌 2020 ; 124 : 1490-8.
 
11) Nishiyama M, et al. Fosphenytoin vs. continuous midazolam for pediatric febrile status epilepticus. Brain Dev 2018 ; 40 : 884-0.
PubMed
12) Nakazawa M, et al. Efficacy and safety of fosphenytoin for acute encephalopathy in children. Brain Dev 2015 ; 37 : 418-22.
PubMed
13) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2017. p. 40-5.
 
14) 日本小児神経学会監. 小児けいれん重積治療ガイドライン策定ワーキンググループ編. 小児けいれん重積治療ガイドライン 2017. 東京 : 診断と治療社 ; 2017. p. 47-52.
 
15) Claassen J, et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsivestatus epilepticus. Neurology 2001 ; 57 : 1036-42.
PubMed
16) 日本小児神経学会監, 小児けいれん重積治療ガイドライン策定ワーキンググループ編. 小児けいれん重積治療ガイドライン 2017. 東京 : 診断と治療社 : ; 2017. p. 53-8.
 
P.89 掲載の参考文献
1) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
2) American Heart Assocjation. PALSプロバイダーマニュアルAHAガイドライン 2020 準拠, 東京 : シナジー ; 2021
 
3) Kochanek PM, et al. Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition : Update of the Brain Trauma Foundation Guidelines. Pediatr Crit Care Med 2019 ; 20 : S1-82.
PubMed
4) Pfenninger J, et al. Treatment and outcome of the severely head injured child. Intensive Care Med 1983 ; 9 : 13-6.
PubMed
5) Esparza J, et al. Outcome in children with severe head injuries. Childs Nerv Syst 1985 ; 1 : 109-14.
PubMed
6) Alberico AM, et al. Outcome after severe head injury. Relationship tomass lesions, diffuse injury, and ICP course in pediatric and adult patients. J Neurosurg 1987 ; 67 : 648-56.
 
7) Kasoff SS, et al. Aggressive physiologic monitoring of pediatric head trauma patients with elevated intracranial pressure. Peditr Neurosci 1988 ; 14 : 241-9.
 
8) Grinkeviciute DE, et al. Significance of intracranial pressure and cerebral perfusion pressure in severe pediatric traumatic brain injury. Medicina (Kaunas) 2008 ; 44 : 119-25.
PubMed
9) Downard C, et al. Relationship of cerebral perfusion pressure and survival in pediatric brain-injured patients. J Trauma 2000 ; 49 : 654-8.
PubMed
10) Peterson B, et al. Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients. Crit Care Med 2000 ; 28 : 1136-43.
PubMed
11) Dominguez TE, et al. Caution should be exercised when maintaining a serum sodium level > 160 meq/L. Crit Care Med 2004 ; 32 : 1438-40.
PubMed
12) The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Use of mannitol. J Neurotrauma 2000 ; 17 : 521-5.
 
13) Becker DP, Vries JK. The alleviation of increased intracranial pressure by the chronic administration of osmotic agents. In : Brock M, Dietz H. eds. Intracranial Pressure. Berlin, Heidelbery : Springer ; 1972. p. 309-15.
 
14) Feig PU, McCurdy DK. The hypertonic state. N Engl J Med 1977 ; 297 : 1444-54.
 
15) Abend NS, et al. Impact of continuous EEG monitoring on clinical management in critically ill children. Neurocriti Care 2011 ; 15 : 70-5.
PubMed
16) Topjian AA, et al. Electrographic status epilepticus is associated with mortality and worse short-term outcome in critically children. Crit Care Med 2013 ; 41 : 215-23.
PubMed
P.94 掲載の参考文献
1) Polderman KH. Induced hypothermia and fever control for prevention and treatment or neurological injuries. Lancet 2008 ; 371 : 1955-69.
 
2) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016. p. 52-5.
 
3) Nielsen N, et al. Targeted temperature management at 33℃ versus 36℃ after cardiac arrest. N Engl J Med 2013 ; 369 : 2197-206.
 
4) Dankiewicz J, et al. Hypothermia versus normothermia after out-of-hospital cardiac Arrest. N Engl J Med 2021 ; 384 : 2283-94.
PubMed
5) Moler FW, et al. Therapeutic hypothermia after out-or-hospital cardiac arrest in children. N Engl J Med 2015 ; 372 : 1898-908.
 
6) Moler FW, et al. Therapeutic hypothermia after in-hospital cardiac arrest in children. N Engl J Med 2017 ; 376 : 318-29.
PubMed
7) Kawano G, et al. Determinants of outcomes following acute child encephalopathy and encephalitis : pivotal effect of early and delayed cooling. Arch Dis Child 2011 ; 96 : 936-41.
PubMed
8) Nishiyama M, et al. Targeted temperature management of acute encephalopathy without AST elevation. Brain Dev 2015 ; 37 : 328-33.
PubMed
9) Hoshide M, et al. Efficacy of hypothermia therapy in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2020 ; 42 : 515-22.
PubMed
10) Murata S, et al. Targeted temperature management for acute encephalopathy in a Japanese secondary emergency medical care hospital. Brain Dev 2016 ; 38 : 317-23.
 
P.102 掲載の参考文献
1) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
2) Hayakawa I, et al. Recent treatment patterns and variations for pediatric acute encephalopathy in Japan. Brain Dev 2020 ; 42 : 48-55. doi : 10.1016/j.braindev.2019.08.007.
 
3) 河島尚志ほか. メチルプレドニゾロン・パルス療法. 小児内科 2013 ; 45 : 234-8.
Medical*Online
4) Okumura A, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev 2009 ; 31 : 221-7.
PubMed
5) 浜野晋一郎. 免疫グロブリン大量療法. 小児内科 2013 ; 45 : 239-41.
Medical*Online
6) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdr
 
7) 平野浩一. 血液浄化療法. 小児内科 2013 ; 45 : 242-4.
Medical*Online
8) Okajima K, et al. Early therapeutic plasma exchange may lead to complete neurological recovery in moderate to severe influenza-associated acute necrotizing encephalopathy. Brain Dev. 2022 : S0387-7604 (22) 00051-1. doi : 10.1016/j.braindev.2022.03.004. Online ahead of print.
 
9) Omata T, et al. Drugs indicated for mitochondrial dysfunction as treatments for acute encephalopathy with onset or febrile convulsive status epileptics. J Neurol Sci 2016 ; 360 : 57-60.
PubMed
10) Fukui KO, et al. Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack or acute encephalopathy with biphasic seizures and late reduced diffusion : a case control study. Brain Dev 2019 ; 41 : 618-24. doi : 10.1016/j.braindev.2019.02.015.
PubMed
11) Akiyama T, et al. Vitamin B6 in acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2020 ; 42 : 402-7. doi : 10.1016/j.braindev.2020.02.002.
 
12) 石井ちぐさほか. けいれん重積型急性脳症への早期ビタミンB6投与経験. 日小児救急医会誌 2009 ; 8 : 35-41.
 
13) Matsuo M, et al. Efficacy of dextromethorphan and cyclosporine a for acute encephalopathy. Pediatr Neurol 2013 ; 48 : 200-5. doi : 10.1016/j.pediatrneurol.2012.11.003.
 
14) Watanabe Y, et al. Cyclosporine for acute encephalopathy with biphasic seizures and late reduced diffusion. Pediatr Int 2014 ; 56 : 577-82. doi : 10.1111/ped.12288.
 
P.107 掲載の参考文献
1) 厚生労働省インフルエンザ脳症研究班. インフルエンザ脳症ガイドライン [改訂版], 2009. http://www.mhlw.go.jp/kinkyu/kenkou/influenza/hourei/2009/09/dl/info0925-01.pdf
 
2) Tada H, et al. Predictive score for early diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion (AESD). J Neurol Sci 205 ; 358 : 62-5.
 
3) Yokochi T, et al. Prediction of acute encephalopathy with biphasic seizures and late reduced diffusion in patients with febrile status epilepticus. Brain Dev 2016 ; 38 : 217-24.
PubMed
4) Fukui KO, et al. Early administration of vitamins B0 and B6 and l-carnitine prevents a second attack or acute encephalopathy with biphasic seizures and late reduced diffusion : a case control study. Brain Dev 2019 ; 41 : 618-24.
PubMed
5) 石井ちぐさほか. けいれん重積型急性脳症への早期ビタミンB6投与経験. 日小児救急医会誌 2009 ; 8 : 35-41
 
6) 林拓也ほか. 脳炎・脳症・髄膜炎の支持療法-全身管理. 小児内科 2013 ; 45 : 215-8.
Medical*Online
7) 永瀬裕朗ほか. 【私の処方 2015】神経・筋疾患の処方 急性脳症の管理. 小児科臨床 2015 ; 68 : 733-41.
 
8) Matsuo M, et al. Efficacy of dextromethorphan and cyclosporine a for acute encephalopathy. Pediatr Neurol 2013 ; 48 : 200-5.
PubMed
9) 田中学ほか. 小児8例におけるエダラボンの使用経験. 小児科臨床 2007 ; 60 : 273-6.
 
10) 河島尚志ほか. フリーラジカルとサイトカインからみたインフルエンザ脳症におけるラジカルスカベンジャー使用経験. 小児科臨床 2008 ; 61 : 1639-43.
Medical*Online
11) Hayashi N, et al. Prognostic factors in acute encephalopathy with reduced subcortical diffusion. Brain Dev 2012 ; 34 : 632-9.
PubMed
12) 奥村彰久. けいれん重積型 (二相性) 脳症 治療 1 : ステロイドは有効か? 小児科臨床 2012 ; 65 : 1965-9
 
13) 池田尚広ほか. 早期ステロイドパルス療法によるけいれん重積型急性脳症発症予防効果の検討. 脳と発達 2014 ; 46 : S304.
Medical*Online
P.112 掲載の参考文献
1) 永瀬裕朗ほか. 【私の処方 2018】神経・筋疾患の処方 急性脳症の管理. 小児科臨床 2018 ; 71 : 790-801.
 
2)Tomioka K, et al. Detailed clinical course of fatal acute encephalopathy in children. Brain Dev 2019 ; 41 : 691-8.
 
3) Adams ST, Leveson SH. Clinical prediction rules. BMJ 2012 ; 344 : d8312.
PubMed
4) Nagase H, et al. Therapeutic indicators or acute encephaiopathy in patients with complex febrile seizures. Pediatr Int 2013 ; 55 : 310-4.
 
5) Yokochi T, et al. Prediction of acute encephalopathy with biphasic seizures and late reduced diffusion in patients with febrile status epilepticus. Brain Dev 2016 ; 38 : 217-24.
PubMed
6) Tada H, et al. Predictive score for early diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2015 ; 1358 : 62-5.
 
7) Nishiyama M, et al. Targeted temperature management of acute encephalopathy without AST elevation. Brain Dev 2015 ; 37 : 328-33.
PubMed
7) Sasaki K, et al. Clinical prediction rule for neurological sequelae due to acute encephalopathy a medical community-based validation study in Harima, Japan. BMJ Open 2017 ; 7 : e016675.
PubMed
8) Nishiyama M, et al. Prediction of AESD and neurological sequelae in febrile status epilepticus. Brain Dev 2021 ; 43 : 616-25.
PubMed
10) Lawrence DM, et al. Status epilepncus. In : Swaiman KF, et al. Swaiman's Pediatric Neurology : Principles and Practice. 5th ed. Philadelphia PA : Elsevier ; 2012. p. 800-1.
 
11) 丸山あずさほか. 遷延性熱性発作を呈した小児における非けいれん性発作. 日児誌 2014 ; 118 : 1475-80.
 
12) Fujita K, et al. Non-convulsive seizures in children with infection-related altered mental status. Pediatr Int 2015 ; 57 : 659-64.
PubMed
13) Yamaguchi H, et al. Nonconvulsive seizure detection by reduced-lead electroencephalography in children with altered mental status in the emergency department. J Pediatr 2019 ; 207 : 213-9.
PubMed
14) Maruyama A, et al. Early non-convulsive seizures are associated with the development of acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2021 ; 43 : 548-55.
PubMed
15) Polderman KH. Induced hypothermia and fever control for prevention and treatment of neurological injuries. Lancet 2008 ; 371 : 1955-69.
PubMed
16) 佐治洋介ほか. 小児急性脳炎・脳症に対するデキサメサゾン併用脳低温療法の神経学的予後に対する有用性検討. 日小児救急医会誌 2011 ; 10 : 22-6.
 
17) Tanaka T, et al. predicting the outcomes of targeted temperature management for children with seizures and/or impaired consciousness accompamed by fever without known etiology. Brain Dev 2019 ; 41 : 604-13.
PubMed
18) Ishida Y, et al. Thiamylal anaesthetic therapy for febrile refractory status epilepticus in children. Seizure 2020 ; 80 : 12-7.
PubMed
19) Ishida Y, et al. Early steroid pulse therapy for children with suspected acute encephalopathy. An observational study. Medicine (Baltimore) 2021 ; 100 : e26660.
PubMed
20) Yamaguchi H, et al. Elevated cytokine, chemokine, and growth and differentiation factor-15 levels in hemorrhagic shock and encephalopathy syndrome : a retrospective observational study. Cytokine 2021 ; 137 : 155324.
PubMed
21) Gosalakkal JA, et al. Reye syndrome and Reye-like syndrome. Pediatr Neurol 2008 ; 39 : 198-200.
PubMed
P.122 掲載の参考文献
1) 栗原まな. 後天性脳損傷児に対する早期リハビリテーションの重要性-救急医療との連携を目指して. 日児誌 2009 ; 113 : 1519-30.
 
2) 栗原まな. 小児の後天性脳損傷. 日児誌 2017 ; 121 : 1945-54.
 
3) 栗原まな. 小児神経疾患のリハビリテーション総論 : 他科・多職種との連携の重要性. 脳と発達 2017 ; 49 : 181-6.
Medical*Online
4) 栗原まな. 小児脳損傷後の回復. 日脳外会誌 2016 ; 25 : 330-7.
 
5) 栗原まなほか. 急性脳症後遺症の検討. 脳と発達 2011 ; 43 : 285-90.
Medical*Online
6) 栗原まな. わかりやすい小児の高次脳機能障害対応マニュアル. 東京 : 診断と治療社 ; 2009.
 
7) 栗原まなほか. 急性脳症罹患後に生じた視覚認知障害の検討. 脳と発達 2013 ; 45 : 299-303.
Medical*Online
8) 栗原まなほか. 急性脳症罹患後に発症したてんかん : 重度後遺症合併例における検討. 日児誌 2003 ; 107 : 46-52.
 

4章 急性脳炎・急性脳症の臨床

P.133 掲載の参考文献
1) 日本小児神経学会監, 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
2) Takanashi J, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006 ; 66 : 1304-9.
PubMed
3) Takanashi J. Two newly proposed encephalitis/encephalopathy syndromes. Brain Dev 2009 ; 31 : 521-8.
PubMed
4) 高梨潤一. けいれん重積型 (二相性) 急性脳症 (AESD) の病態・診断・治療. 小児科 2021 ; 62 : 939-48
 
5) Hoshino A, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndrome. Brain Dev 2012 ; 34 : 337-43.
PubMed
6) Kasai M, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-12.
PubMed
7) Hirayama Y, et al. "Symptomatic" infection-associated acute encephalopathy in children with underlying neurological disorders. Brain Dev 2017 ; 39 : 243-7.
PubMed
8) Ichinose F, et al. Incidence and risk factors of acute encephalopathy with biphasic seizures in febrile status epilepticus. Brain Dev 2022 ; 44 : 36-43.
PubMed
9) Takanashi J, et al. Disrupted glutamate-glutamine cycle in acute encephalopathy with biphasic seizures and late reduced diffusion. Neuroradiology 2015 ; 57 : 1163-8.
PubMed
10) Takanashi J, et al. Excitotoxicity in acute encephalopathy with biphasic seizures and late reduced diffusion. Report of 3 cases. AJNR Am J Neuroradiol 2009 ; 30 : 132-5.
 
11) Ichiyama T, et al. Serum and CSF levels of cytokines in acute encephalopathy following prolonged febrile seizures. Brain Dev 2008 ; 30 : 47-52.
PubMed
12) Takanashi J, et al. Loss of myelinated axons and astrocytosis in an autopsy case of acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2018 ; 40 : 947-51.
 
13) Komatsu M, et al. Clustered subclinical seizures in a patient with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2010 ; 32 : 472-6.
 
14) Ito Y, et al. Seizure characteristics of epilepsy in childhood after acute encephalopathy with biphasic seizures and late reduced diffusion. Epilepsia 2015 ; 56 : 1286-93.
PubMed
15) Uetani H, et al. Perfusion abnormality on three-dimensional arterial spin labeling in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2020 ; 408 : 116558.
PubMed
16) Tada H, et al. Predictive score for early diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion (AESD), J Neurol Sci 2015 ; 358 : 62-5.
PubMed
17) Nishiyama M, et al. Targeted temperature management of acute encephalopathy without AST elevation. Brain Dev 2015 ; 37 : 328-33.
PubMed
18) Yokochi T, et al. Prediction of acute encephalopathy with biphasic seizures and late reduced diffusion in patients with febrile status epilepticus. Brain Dev 2016 ; 38 : 217-24.
PubMed
19) Nagase H, et al. Therapeutic indicators of acute encephalopathy in patients with complex febrile seizures. Pediatr Int 2013 ; 55 : 310-4.
PubMed
20) 市坂有基ほか. 二相性脳症における早期治療介入基準についての比較検討及びその活用. 日小児救急医会誌 2018 ; 17 : 396-400.
 
21) 石田悠介ほか. 急性脳症の予測基準の有用性の検証 : 第1報 AESD予測のために開発された基準の別コホートにおける再検証. 脳と発達 2020 ; 52 : S264.
Medical*Online
22) Takase N, et al. Infantile traumatic brain injury with a biphasic clinical course and late reduced diffusion. J Neurol Sci 2018 ; 390 : 63-6.
PubMed
23) 後藤知英ほか. 急性脳症他施設研究・レジストリーの経過と成果 : 関東地区から. 脳と発達 2020 ; 52 : S81.
 
P.140 掲載の参考文献
1) Tada H, et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 2004 ; 63 : 1854-8.
PubMed
2) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
3) 多田弘子ほか. 可逆性脳梁膨大部病変を有する軽症脳炎脳症-up-to-date. 日児誌 2019 ; 123 : 814-23
 
4) Kasai M, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-12.
PubMed
5) Hayashi M, et al. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci 2020 ; 15 : 415.
 
6) Galcia-Monco JC, et al. Reversible splenial lesion syndrome (RESLES) : what's in a name? J Neuroimaging 2011 ; 21 : e1-14.
 
7) Takanashi J, et al. Encephalopathy with a reversible splenial lesion is associated with hyponatremia. Brain Dev 2009 ; 31 : 217-20.
PubMed
8) Takanashi J, et al. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brin Dev 2009 ; 31 : 521-8.
 
9) Imamura T, et al. Sisters with clinically mild encephalopathy with a reversible splenial lesion (MERS) -like features : Familial MERS? J Neuro Sci 2010 ; 290 : 153-6.
 
10) Kouga T, et al. A child with three episodes of reversible splenial lesion. Neuropediatrics 2013 ; 44 : 192-202.
 
11) Kurahashi H, et al. MYRF is associated with encephalopathy with a reversible myelin vacuolization. Ann Neurol 2018 ; 83 : 98-106.
PubMed
12) Suzuki Y, et al. Estimation of the mean axon diameter and intra-axonal space volume fraction on the human corpus callosum : diffusion-q-space imaging with low q-values. Magn Reson Mer Sci 2016 ; 14 : 83-93.
 
13) Takanashi J, et al. Differences in the time course of splenial and white matter lesions in clinically meld encephalitis/encephalopathy with a reversible splenial lesion (MERS). J Neurol Sci 2010 ; 292 : 24-7.
 
14) Xue J, et al. A cohort study or mild encephalitis/encephalopathy with a reversible splenial lesion in children. Brain Behav 2021 ; 11 : e2306.
PubMed
15) Takanashi J, et al. Widening spectrum of a reversible splenial lesion with transiently reduced diffusion. AJNR Am J Neuroradiol 2006 ; 27 : 836-8.
PubMed
16) Miyata R, et al. Oxidative stress in patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). Brain Dev 2012 ; 34 : 124-7.
PubMed
17) Kawahara Y, et al. Serum and cerebrospinal fluid cytokines in children with acute encephalopathy. Brain Dev 2020 ; 42 : 185-91.
PubMed
18) Takanashi J, et al. Clinical and radiological features or rotavirus cerebellitis. AJNR Am J Neuroradiol 2010 ; 31 : 1591-5.
 
19) Mizutani M, et al. Distinctive inflammatory profile between acute focal bacterial nephritis and acute pyelonephritis in children. Cytokine 2017 ; 99 : 24-9.
PubMed
20) Okada T, et al. Increased cytokines/chemokines and hyponatremia as a possible cause of clinically mild encephalitis/encephalopathy with a reversible splenial lesion associated with acute focal bacterial nephritis. Brain Dev 2021 Jul 28 ; S0387-7604 (21) 00136-4. doi : 10.1016/j.braindev.2021.07.008. online ahead of print.
 
21) Takanashi J, et al. Clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination. J Neurol Sci 2015 ; 349 : 226-8.
PubMed
22) 屋代真弓, 上原里程. 第21回川崎病全国調査成績. 小児科臨床 2012 ; 75 : 507-23.
 
23) Kashiwagi M, et al. Clinico-radiological spectrum of reversible splenial lesions in children. Brain Dev 2014 ; 36 : 330-6.
PubMed
24) 日本医療研究開発機構研究費 新型インフルエンザ等への対応に関する研究班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
P.147 掲載の参考文献
1) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 : 2016.
 
2) Levin M, et al. Haemorrhagic shock and encephalopathy : a new syndrome with a high mortality in yound chidren. Lancet 1983 ; 2 : 64-7.
 
3) Gefen R, et al. Hemorrhagic shock and encephalopathy syndrome : clinical course and neurological outcome. J Chile Neurol 2008 ; 23 : 589-92.
 
4) Kasai M, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
PubMed
5) Sofer S, et al. Possible aetiology of haemorrhagic shock and encephalopathy syndrome in the Negev area of Israel. Arch Dis Child 1996 ; 75 : 332-4.
PubMed
6) Thebaud B, et al. Haemorrhagic shock and encephalopathy of outcome. Intensive Care Med 1999 ; 25 : 293-9.
PubMed
7) Rinka H, et al. Hemorrhagic shock and encephalopathy syndrome : the markers for an early HSES diagnosis. BMC Pediatr 2008 ; 8 : 43.
PubMed
8) Bacon CJ, et al. Case control study of thermal environment preceding haemorrhagic shock encephalopathy syndrome. Arch Dis Child 1999 ; 81 : 155-8.
PubMed
9) Yamaguchi H, et al. Elevated cytokine, chemokine, and growth and differentiation factor 15 levels in hemorrhagic shock and encephalopathy syndrome : a retrospective observational study. Cytokine 2021 ; 137 : 155324.
PubMed
10) Levin M, et al. Hemorrhagic shock and encephalopathy : clinical, pathologic, and biochemical features. J Pediatrl 1989 ; 14 : 194-203.
PubMed
11) Bacon CJ, Hall SM. Haemorrhagic shock encephalopathy syndrome in the British Isles. Arch Dis Child 1992 ; 67 : 985-93.
PubMed
12) Jardine DS, Bratton SL. Using characteristic changes in laboratory values to assist in the diagnosis of hemorrhagic shock and encephalopathy syndrome. Pediatrics 1995 ; 96 : 1126-31.
PubMed
13) Morishima T, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002 ; 35 : 512-7.
PubMed
14) 塩見正司ほか. インフルエンザ脳症の急性期臨床神経画像所見. 日本臨床 2006 ; 64 : 1887-9.
Medical*Online
15) Harden A, et al. EEG features and their evolution in the acute phase of haemorrhagic shock and encephalopathy syndrome. Neuropediatrics 1991 ; 22 : 194-7.
PubMed
P.153 掲載の参考文献
1) Mizuguchi M, et al. Acute necrotising encephalopathy of childhood : a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry 1995 ; 58 : 555- 61.
 
2) Mizuguchi M. Acute necrotizing encephalopathy of childhood : a novel form of acute encephalopathy prevalent in Japan and Taiwan. Brain Dev 1997 ; 19 : 81-92. doi : 10.1016/s0387-7604 (96) 00063-0.
 
3) Ichiyama T, et al. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virusassociated encephalopathy. Scand J Infect Dis 2003 ; 35 : 59-61.
PubMed
4) Song Y, et al. Influenza-associated encephalopathy and acute necrotizing encephalopathy in children : a retrospective single-center study. Med Sci Monit 2021 ; 27 : e928374. doi : 10.12659/MSM.928374.
 
5) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
6) 水口雅. 急性壊死性脳症 (ANE). 塩見正司編. 小児科臨床ピクシス 28. 急性脳炎・急性脳症. 東京 : 中山書店 ; 2011. p. 174-7
 
7) Yoshida T, et al. MRI gadolinium enhancement precedes neuroradiological findings in acute necrotizing encephalopathy. Brain Dev 2013 ; 35 : 921-4.
PubMed
8) Tenembaum S, et al. Acute disseminated encephalomyelitis : a long-term follow-up study of 84 pediatric patients. Neurology 2002 ; 59 : 1224-31.
PubMed
9) Nishiyama M, et al. Clinical time course or pediatric acute disseminated encephalomyelitis. Brain Dev 2019 ; 41 : 531-7. : 10.1016/j.braindev.2019.02.011.
 
10) Dangi S, Gwasikoti N. A case of deep cerebral venous thrombosis presenting like acute necrotizing encephalopathy. J Pediatr Neurosci 2020 ; 15 : 54-6. doi : 10.4103/JPN.JPN_117_19.
 
11) Leach JL, et al. Cerebral venous thrombus signal intensity and susceptibility effects on gradient recalled-echo MR imaging. AJNR Am J Neuroradiol 2007 ; 28 : 940-5
PubMed
12) Kurahashi N, et al. Thalamic lesions in acute encephalopathy with biphasic seizures and late reduced diffusion. Pediatr Neurol 2014 ; 51 : 701-5. doi : 10.1016/j.pediatrneurol.2014.07.013. Epub 2014 Jul 16. PMID : 25193414.
 
13) Neilson DE, et al. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet 2009 ; 84 : 44-51.
 
14) Okumura A, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev 2009 ; 31 : 221-7.
PubMed
15) Li K, Plasma exchange therapy for acute necrotizing encephalopathy of childhood. Pediatr Investig 2021 ; 5 : 99-105. doi : 10.1002/ped4.12280.
 
P.161 掲載の参考文献
1) Awaya Y, Fukuyama Y. Epilepsy sequelae of acute encephalitis or encephalopathy (3rd report). Jpn J Psychiatr Neurol 1986 ; 40 : 385-7.
PubMed
2) 塩見正司ほか. 頻回のけいれんを伴う急性脳症の6症例. 脳と発達 1988 ; 20 (Suppl) : s195.
 
3) 佐久間啓ほか. Acute encephalitis with refractory, repetitive partial seizuresの治療に関する検討. 脳と発達 2001 ; 121 : 251-6.
 
4) Wilder-Smith EP, et al. The NORSE (new-onset refractory status epilepticus) syndrome : difining a disease entity. Ann Acad Med Singap 2005 ; 34 : 417-20.
 
5) Van Baalen A, et al. Febrile infection-related epilepsy syndrome (FIRES) : a nonencephalitic encephalopathy in childhood. Epilepsia 2010 ; 51 : 1323-8.
PubMed
6) Gaspard N, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) : state of the art and perspectives. Epilepsia 2018 ; 59 : 745-52.
PubMed
7) Hoshino A, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev 2012 ; 34 : 337-43.
PubMed
8) Sakuma H, et al. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatr 2015 ; 86 : 820-2.
 
9) 粟屋豊ほか. 頻回難治複雑部分発作重積症を呈する非ヘルペス性脳炎-そのてんかん原性, 長期経過および文献例の検討. 脳と発達 2007 ; 39 : 138-44.
Medical*Online
10) Okumura A, et al. Amplitude-integrated electroencephalography in patients with acute encephalopathy with refractory, repetitive partial seizures. Brain Dev 2011 ; 33 : 77-82.
PubMed
11) Helbig I, et al. Whole-exome and HLA sequencing in Febrile infection-related epilepsy syndrome. Ann Clin Transl Neurol 2020 ; 7 : 1429-35.
PubMed
12) Saitoh M, et al. Cytokine-related and sodium channel polymorphism as candidate predisposing factors for childhood encephalopathy FIRES/AERRPS. J Neurol Sci 2016 ; 368 : 272-6.
PubMed
13) Sakuma H, et al. Neurocritical care and target immunotherapy for febrile infection related epilepsy syndrome. Biomed J 2020 ; 43 : 205-210.
PubMed
14) Kramer U, et al. Febrile infection-related epilepsy syndrome (FIRES) : pathogenesis, treatment, and outcome : a multicenter study on 77 children. Epilepsia 2011 ; 52 : 1956-65.
PubMed
15) Nabbout R, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010 : 51 : 2033-7.
PubMed
16) Singh RK, et al. Cognitive outcomes in febrile infection-related epilepsy syndrome treated with the ketogenic diet. Pediatrics 2014 ; 134 : e1431-5.
PubMed
17) Lai YC, et al. Anakinra usage in febrile infection related epilepsy syndrome : an international cohort. Ann Clin Transl Neurol 2020 ; 7 : 2467-74.
PubMed
18) Jun JS, et al. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol 2018 ; 84 : 940-5.
PubMed
19) Horino A, et al. Intrathecal dexamethasone therapy for febrile infection-related epilepsy syndrome. Ann Clin Transl Neurol 2021 ; 8 : 645-55.
PubMed
20) Saito Y, et al. Acute encephalitis with refractory, repetitive partial seizures : case reports of this unusual postencephalitic epilepsy. Brain Dev 2007 ; 29 : 147-56.
PubMed
21) Lin JJ, et al. Effect of topiramate, in combination with lidocaine, and phenobarbital, in acute encephalitis with refractory repetitive partial seizures. Brain Dev 2009 ; 31 : 605-11.
PubMed
22) Ueda R, et al. Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase. Brain Dev 2015 ; 37 : 471-7.
PubMed
P.166 掲載の参考文献
1) Reye RD, et al. Encephalopathy and fatty degeneration or the viscera. a disease entity in childhood. Lancet 1963 ; 2 : 749-52.
PubMed
2) Hurwitz ES, et al. Public Health Service study of Reye's syndrome and medications, Report or the main study. JAMA 1987 ; 257 : 1905-11.
 
3) Belay ED, et al. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 1999 ; 340 : 1377-82.
PubMed
4) Uppala R, et al. Aspirin increases mitochondrialfatty acid oxidation. Biochem Biophys Res Commun 2017 ; 482 : 346-51.
 
5) 小児栄養消化器肝臓学会編. 小児栄養消化器肝臓病学. 東京 : 診断と治療社 ; 2014. p. 469-71.
 
6) Centers for Disease Control and Prevention. Follow-up Reye syndrome-United States. MMWR 1980 ; 29 : 321-2.
 
7) 木村昭. 【急性脳炎・脳症】急性脳炎・脳症の病因・病態 Reye症候群・Reye様症候群. 日本臨床 2011 ; 69 : 455-9.
 
8) 木村清ほか. 感染に伴う急性脳症35例の臨床的検討. 脳と発達 1998 ; 30 : 244-9.
Medical*Online
9) Chapman J, Arnold JK. Reye syndrome. In : StatPearls [Internet], Treasure Island (FL) : StatPearls Publishing ; 2021 Jan, 2021 Jul 10.
 
10) Rochat RW, et al. Maternal and child health epidemic-assistance investigations, 1946-2005. Am J Epidemiol 2011 ; 174 : S80-8.
PubMed
11) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016. p. 62-3.
 
12) Ferretti S, et al. Atypical Reye syndrome : three cases or a problem that pediatricians should consider and remember. Acta Biomed 2021 ; 92 : e2021110.
PubMed
13) Chang PF, et al. Metabolic disorders mimicking Reye's syndrome. J Formos Med Assoc 2000 ; 99 : 295-9.
PubMed
14) Pugliese A, et al. Reye's and Reye's-like syndromes. Cell Biochem Funct 2008 ; 26 : 741-6.
PubMed
15) Ichikawa K, et al. Acute encephalopathy of Bacillus cereus mimicking Reye syndrome. Brain Dev 2010 ; 32 : 688-90.
PubMed
16) Shiota M, et al. Rapid detoxification or cereulide in Bacillus cereus food poisoning. Pediatrics 2010 ; 125 : e951-5.
PubMed
17) Andersson MA, et al. Toxicological profile of cereulide, the Bacillus cereus emetic toxin, in functional assays with human, animal and bacterial cells. Toxicon 2007 ; 49 : 351-67.
PubMed
P.176 掲載の参考文献
1) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf (最終閲覧 2021年8月)
 
2) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
3) 奥村彰久ほか. 2009-2010 シーズン以降の小児のインフルエンザ脳症の実態. Neuroinfection 2016 ; 21 : 115-20.
 
4) Kasai M, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
PubMed
5) Okumura A, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev 2009 ; 31 : 221-7.
PubMed
6) Kurahashi H, et al. MYRF is associated with encephalopathy with reversible myelin vacuolization. Ann Neurol 2018 ; 83 : 98-106.
PubMed
7) Okumura A, et al. Acute necrotizing encephalopathy : a comparison between influenza and non-influenza cases. Microbiol Immunol 2009 ; 53 : 277-80.
PubMed
P.185 掲載の参考文献
1) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
2) Hoshino A, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev 2012 ; 34 : 337-43.
PubMed
3) 奥野英雄ほか. 当院で経験した急性脳症の原因病原体について. 小児感染免疫 2014 ; 26 : 41-7.
 
4) Kuki I, et al. MRI findings at neurological onset predict neurological prognosis in hemorrhagic shock and encephalopathy syndrome. J Neurol Sci 2021 ; 430 : 120010.
PubMed
5) Kawabe S, et al. Comparison of the levels of human herpesvirus 6 (HHV-6) DNA and cytokines in the cerebrospinal fluid and serum of children with HHV-6 encephalopathy. J Med Virol 2010 ; 82 : 1410-5.
PubMed
6) 井上岳司. 急性脳症-小児神経救急臨床からのアプローチ. 日小児救急医会誌 2020 ; 19 : 171-80.
 
7) 福岡正隆ほか. けいれん重積型 (二相性) 急性脳症発症の早期予測因子の検討. 脳と発達 2021 ; 53 : 28-32.
Medical*Online
8) 林下浩士ほか. 脳腫脹が進行する急性脳症の早期診断の指標-代謝性アシドーシスが2時間持続する症例は熱性痙攣ではない. 日小児救急医会誌 2011 ; 10 : 9-13.
 
9) 井上岳司ほか. 当院救急外来でペーパレス脳波を施行した症例の臨床的検討. 脳と発達 2012 ; 44 : 305-9
 
10) Miura H, et al. Chromosomally integrated human herpesvirus 6 in the Japanese population. J Med Virol 2018 ; 90 : 1636-42.
PubMed
11) Clark DA, et al. Transmission of integrated human herpesvirus 6 through stem cell transplantation : implications for laboratory diagnosis. J Infect Dis 2006 ; 193 : 912-6.
PubMed
12) 緒方正男ほか. 造血細胞移植ガイドライン-ウイルス感染症の予防と治療 HHV-6. JSHCT monograph 2018 ; 50. https://www.jshct.com/uploads/files/guideline/01-03_03_hhv6.pdf
 
13) Ogata M, et al. Clinical characteristics and outcome of humam herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2017 ; 52 : 1563-70.
 
14) Ogata M, et al. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation : a multicenter, prospective study. Clin Infect Dis 2013 ; 57 : 671-81.
PubMed
P.196 掲載の参考文献
1) Roizman B, et al. Herpes simplex viruses. In : Knipe D, Howley P, editors. Fields Virology. 6th ed. Philadelphia : Lippincott Williams & Wilkins ; 2013. p. 1823-97.
 
2) Torii Y, et al. Clinicoepidermologic status of mother-to-child infections : a nationwide survey in Japan. Pediatr Infect Dis J 2013 ; 32 : 699-701.
PubMed
3) 日本性感染症学会. 性器ヘルペス. 性感染症診断・治療ガイドライン 2016. 日性感染症会誌 2016 ; 27 : 64-8.
 
4) 森島恒雄. 小児の急性脳炎・脳症の現状. ウイルス 2009 ; 59 : 59-66.
 
5) 日本神経感染症学会, 日本神経学会, 日本神経治療学会. 単純ヘルペス脳炎診療ガイドライン 2017.
 
6) Kimura H, et al. Relapse of herpes simplex encephalitis in children. Pediatrics 1992 ; 89 : 891-4.
PubMed
7) 森島恒雄ほか. 新生児ヘルペス全国調査. 日児誌 1989 ; 93 : 1990-5.
 
8) Kimberlin DW, et al. Natural history or neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001 ; 108 : 223-9.
 
9) Kimberlin DW. Herpes simplex virus infections of the newborn. Semin Perinatol 2007 ; 31 : 19-25.
 
10) Kimura H, et al. Detection of viral DNA in neonatal herpes simplex virus infections : frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis 1991 ; 164 : 289-93.
PubMed
11) Ito Y, et al. Polymerase chain reaction-proved herpes simplex encephalitis in children. Pediatr Infect Dis J 1998 ; 17 : 29-32.
PubMed
12) Bronstein DE, Glaser CA. Encephalitis and meningoencephalitis. In : Cherry JD, et al, editors. Feigin and Cherry's Textbook of Pediatric Infectioug. Diseases. Philadelphia : Elsevier ; 2018. p. 361-75.
 
13) Kimberlin DW, et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med 2011 ; 365 : 1284-92.
PubMed
14) Sergerie Y, et al. Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice. J Infect Dis 2007 ; 195 : 817-25.
 
15) Lizarraga KJ, et al. Are steroids a beneficial adjunctive therapy in the immunosuppressed patient with herpes simplex virus encephalitis? Case Rep Neurol 2013 ; 5 : 52-5.
PubMed
16) Kamei S, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry 2005 ; 76 : 1544-9.
PubMed
17) Meyding-Lamade U, et al. The German trial on aciclovir and corticosteroids in herpes-simplex-virus-encephalitis (GACHE) : a multicenter, randomized, double-blind, placebo-controlled trial. Neurol Res Pract 2019 ; 1 : 26.
 
18) Leypoldt F, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis : case report. Neurology 2013 ; 81 : 1637-9.
PubMed
19) Armangue T, et al. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology 2015 ; 85 : 1736-43.
PubMed
20) Armangue T, et al. Herpes simplex virus encephalitis is a trigger or brain autoimmunity. Ann Neurol 2014 ; 75 : 317-23.
 
21) Armangue T, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalilis after herpes simplex encephalitis : a prospective observational study and retrospective analysis. Lancet Neurol 2018 ; 17 : 760-72.
PubMed
22) Pruss H, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012 ; 72 : 902-11.
PubMed
23) Hacohen Y, et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 2014 ; 29 : 90-6.
PubMed
24) Sutcu M, et al. Role of autoantibodies to Nmethyl-d-aspartate (NMDA) receptor in relapsing herpes simplex encephalitis : a retrospective, one-center experience. J Child Neurol 2016 ; 31 : 345-50.
 
25) Titulaer MJ, et al. Antibodies to N-methyl-Daspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis. Mov Disord 2014 ; 29 : 3-6.
 
26) Titulaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study. Lancet Neurol 2013 ; 12 : 157-65.
PubMed
27) Florance NR, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009 ; 66 : 11-8.
 
28) Suppiej A, et al. Plasma exchange in pediatric anti-NMDAR encephalitis : a systematic review. Brain Dev 2016 ; 38 : 613-22.
PubMed
29) Omae T, et al. Cytokine/chemokine elevation during the transition phase from HSV encephalitis to autoimmune anti-NMDA receptor encephalitis. Brain Dev 2018 ; 40 : 361-5.
PubMed
P.201 掲載の参考文献
1) 成田光生. 肺炎マイコプラズマ感染による肺外発症. 臨床小児医学 2010 ; 158 : 3-8.
 
2) Quanquin NM, Cherry JD. Mycoplasma and ureaplasma infections. In : Cherry JD, et al. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 8th ed. Elsevier ; 2018. p. 1976-91.
 
3) Guleria R, et al. Mycoplasma pneumoniae and central system complications : a review. J Lab Clin Med 2005 ; 146 : 55-63.
PubMed
4) 金森透ほか. マイコプラズマ脳炎・脳症8例の臨床的検討. 脳と発達 2018 ; 50 : 50-4.
Medical*Online
5) Tsiodras S, et al. Central nervous system manifestations of Mycoplama peumoniae infections. J Inrect 2005 ; 51 : 343-54.
 
6) Christie LJ, et al. Pediatric encephalisis : what is the role of Mycoplasma pneumoniae? Pediatric 2007 ; 120 : 305-13.
PubMed
7) Narita M. Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection. Pediatr Neurol 2009 ; 41 : 159-66.
PubMed
8) Al-Zaidy SA, et al. Neurological complications of PCR-proven M. pneumoniae infections on children : prodromal illness duraiton may reflect pathogenetic mechanism. Clin Infect Dis 2015 ; 61 : 1092-8.
 
9) 森口直彦. マイコプラズマ脳炎. 小児内科 2013 ; 45-2 : 291-4.
Medical*Online
10) Bitnun A, et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin Infect Dis 2001 ; 32 : 1674-84.
PubMed
11) Chambert-Loir C, et al. Immediate relief of Mycoplasma pneumoniae encephalitis symptoms after intravenous immunoglobulin. Pediatr Neurol 2009 ; 41 : 375-7.
PubMed
12) Sakoulas G. Brainstem and strialal encephalitis complicating Mycoplasma pneumoniae pneumonia : possible bencfit of intravenous immunoglobulin. Pediatr Infect Dis J 2001 ; 20 : 543-5.
PubMed
13) Daxboeck F, et al. Diagnosis, treatment, and prognosis of Mycoplasma pneumoniae childhood encephalitis : systematic review of 58 cases. J Child Neurol 2004 ; 19 : 865-71.
 
P.210 掲載の参考文献
1) The Committee on Infectious Diseases. RedBook 2018. 31st edition. Elk Groove Village : American Academy of Pediatrics ; 2018. p. 310-7.
 
2) Koyano S, et al. Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper : feasibility and outcomes from a multicentre study. BMJ Open 2011 ; 1 : e000118.
PubMed
3) Sato T, et al. Type I interferonopathies : common pathological features between congenital infections and genetic disorders. In : Oohashi T, et al. eds. Human Pathobiochemistry. Springer ; 2019. p. 279-94.
 
4) Luck SE, et al. Congenital cytomegalovirus : an European expert consensus statement on diagnosis and management. Pediatr Infect Dis J 2017 ; 36 : 1205-13.
PubMed
5) Diogo MC, et al. The MRI spectrum of congenital cytomegalovirus infection. Prenatal Diag 2020 ; 40 : 110-24.
PubMed
6) 岡明. 先天性サイトメガロウイルス感染の出生児画像検査. 厚生労働科学研究費補助金成育疾患克服等次世代育成基盤研究事業 : 先天性サイトメガロウイルス感染症対策のための妊婦教育の効果の検討, 妊婦・新生児スクリーニング体制の構成及び感染新生児の発症リスク同定に関する研究. https://www.med.kobe-u.ac.jp/cmv/image.html (最終閲覧 2021年11月)
 
7) 日本造血細胞移植学会. 造血細胞移植ガイドライン ウイルス感染症の予防と治療 サイトメガロウイルス感染症 (第4版), 2018年8月. https://www.jshct.com/uploads/files/guideline/01_03_01_cmv04.pdf (最終閲覧 2021年11月)
 
8) 日本エイズ学会HIV感染症治療委員会. HIV感染症「治療の手引き」. 第24版. 2020年11月. http://www.hivjp.org/guidebook/hiv_24.pdf (最終閲覧 2021年11月)
 
P.218 掲載の参考文献
1) Messacar K, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet 2015 ; 385 : 1662-71.
PubMed
2) Sejvar JJ, et al. Acute flaccid myelitis in the United States, August-December 2014 : results of nationwide surveillance. Clin Infect Dis 2016 ; 63 : 737-45.
PubMed
3) CSTE. https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/ps2021/21-ID-02_AFM.pdf (最終閲覧 2021年11月)
 
4) van Haren K, et al. Acute flaccid myelitis of unknown etiology in California, 2012-2015. JAMA 2015 ; 314 : 2663-71.
PubMed
5) Chong PF, et al. Clinical features of acute flaccid myelitis temporally associated with an enterovirus D68 outbreak : results of a nationwide survey of acute flaccid paralysis in Japan, August-December 2015. Clin Infect Dis 2018 ; 66 : 653-64.
PubMed
6) Greninger AL, et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14) : a retrospective cohort study. Lancet Infect Dis 2015 ; 15 : 671-82.
PubMed
7) Park SW, et al. EpidemioIogical dynamics of enterovirus D68 in the United States and implications for acute flaccid myelitis. Sci Transl Med 2021 ; 13 : eabd2400.
PubMed
8) Elrick MJ, et al. Enterovirus D68 molecular and cellular biology and pathogenesis. J Biol Chem 2021 ; 296 : 100317.
PubMed
9) 吉良龍太郎. エンテロウイルスD68感染症による急性弛緩性麻痺症例に関する臨床的考察. 日児誌 2020 ; 124 : 654-67.
 
10) Kidd S, et al. National surveillance for acute flaccid myelitis : United States, 2018-2020. MMWR Morb Mortal Wkly Rep 2021 ; 70 : 1534-8.
PubMed
11) Sejvar JJ, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003 ; 290 : 511-5.
PubMed
12) Murphy OC, et al. Acute flaccid myelitis : cause, diagnosis, and management. Lancet 2021 ; 397 : 334-46.
PubMed
13) Messacar K, et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018 : an observational cohort study. Lancet Infect Dis 2020 ; 20 : 230-9.
PubMed
14) Okumura A, et al. Serial MRI findings of acute flaccid myelitis during an outbreak of enterovirus D68 infection in Japan. Brain Dev 2019 ; 41 : 443-51.
PubMed
15) 急性弛緩性麻痺を認める疾患のサーベイランス・診断・検査・治療に関する手引き. https://www.niid.go.jp/niid/images/idsc/disease/AFP/AFP-guide.pdf (最終閲覧 2021年11月)
 
16) Chong PF, et al. Clinical and electrophysiological features of acute flaccid myelitis : A national cohort study. Clin Neurophysiol 2021 ; 132 : 2456-63.
PubMed
17) Bjorklund KA, et al. Surgical innovations to restore function in pediatric peripheral nerve conditions. Pediatrics 2021 ; 148 : e2021052556.
PubMed
18) Chong PF, et al. Three-year longitudinal motor function and disability level of acute flaccid myelitis. Pediatr Neurol 2021 ; 116 : 14-9.
PubMed
P.230 掲載の参考文献
1) 日本小児神経学会監. 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
2) 日本先天代謝異常学会編. 新生児マススクリーニング対象疾患等診療ガイドライン 2019. 東京 : 診断と治療社 ; 2019.
 
3) 日本ミトコンドリア学会編. ミトコンドリア病診療マニュアル 2017. 東京 : 診断と治療社 ; 2017.
 
4) 村山圭, 鶴岡智子. 実地臨床に役立つ先天代謝異常症の知識 急性期症状に対する治療のポイント : 高アンモニア血症. 小児科診療 2013 ; 76 : 59-64.
 
5) Brusilow SW, Horwich AL. Urea cycle enzymes. In : Scriver CR, et al. editors. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York : McGraw-Hill ; 2001. p. 1909-63.
 
6) Chuang DT, Shih VE. Maple syrup urine disease. In : Scriver CR, et al. editors. The Metabolic and Molecular Bases or Inherited Disease. New York : McGraw-Hill ; 2001. p. 1971-2005.
 
7) Skladal D, et al. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003 ; 126 : 1905-12.
PubMed
8) Rahman S, et al. Leigh syndrome : clinical features and biochemical and DNA abnormalities. Ann Neurol 1996 ; 39 : 343-51.
PubMed
9) Pavlakis SG, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes : a distmctive clinical syndrome. Ann Neurol 1984 ; 16 : 481-8.
PubMed
10) 小川えりか. バリン代謝異常症としてのECHS1異常症, HIBCH異常症. 遺伝子医学MOOK (1349-2527) 2020 ; 35 : 86-91.
 
11) Mitsubuchi H, et al. Markers associated with inborn errors of metabolism or branched-chain amino acids and their relevance to upper levels of intake in healthy people : an implication from clinical and molecular investigations on maple syrup urine disease. J Nutr 2005 ; 135 : 1565S-1570S.
PubMed
12) チョッケ & ホフマン (松原洋一監訳), 小児代謝疾患マニュアル. 改訂第2版. 東京 : 診断と治療社 ; 2013. p. 1-16, 127-35.
 
13) Saudubray JM, et al. Disorders of mitochondrial fatty acid oxidation and related metabolic pathways. In : Saudubray JM, et al. editors. Inborn Metabolic Disease : Diagnosis and Treatment. 5th ed. Berlin : Springer ; 2012. p. 201-16.
 
14) Bernier FP, et al. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002 ; 59 : 1406-11.
PubMed
15) Kirby DM, et al. Respiratory chain complex 1 deficiency : an underdiagnosed energy generation disorder. Neurology 1999 ; 52 : 1255-64.
 
16) Thorburn DR. Respiratory chain enzyme analysis in muscle and liver. Mitochondrion 2004 ; 4 : 363-75.
PubMed
17) Ohtake A, et al. Diagnosis and molecular basis of mitochondrial respiratory chain disorders : exome sequencing for disease gene identification. Biochim Biophys Acta 2014 ; 1840 : 1355-9.
PubMed
18) Haberle J, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders : first revision. J Inherit Metab Dis 2019 ; 42 : 1192-230. doi : 10.1002/jimd.12100. Epub 2019 May 15. PMID : 30982989.
 
19) Ah Mew N, et al. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate. J Pediatr 2014 ; 165 : 401-3.e403.
 
20) Kido J, et al. Long-term outcome and intervention of urea cycle disorders jn Japan. J Inherit Metab Dis 2012 ; 35 : 777-85. doi : 10.1007/s10545-011-9427-0. Epub 2011 Dec 14. PMID : 22167275.
 
21) Murayama K, Ohtake A. Children's toxicology from bench to bed-Liver Injury (4) : mitochondrial respiratory chain disorder and liver disease in children. J Toxicol Sci 2009 ; 34 Suppl 2 : SP237-43.
 
22) Omata T, et al. Drugs indicated for mitochondrial dysfunction as treatments for acute encephalopathy with onset of febrile convulsive status epileptics. J Neurol Sci 2016 ; 360 : 57-60.
PubMed
23) Shimura M, et al. Effects of 5-aminolevulinic acid and sodium ferrous citrate on fibroblasts from individuals with mitochondrial diseases. Sci Rep 2019 ; 9 : 10549. doi : 10.1038/s41598-019-46772-x. PMID : 31332208 ; PMCID : PMC6646320.
 
24) Distelmaier F, et al. Treatable mitochondrial diseases : cofactor metabolism and beyond. Brain 2017 ; 140 : e11.
PubMed
P.236 掲載の参考文献
1) Dravet C, et al. Dravet syndrome (severe myoclonic epilepsy in infancy), Handb Clin Neurol 2013 ; 111 : 627-33.
PubMed
2) Claes L, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001 ; 68 : 1327-32.
PubMed
3) Miller IO, et al. SCN1A-related seizure disorders. In : Adam MP, et al. editors. GeneReviews [Internet]. Seattle (WA) : University of Washington, Seattle ; 1993-2014. 2007 Nov 29 [updated 2019 April 18], https://www.ncbi.nlm.nih.gov/books/NBK1318/
 
4) Sakauchi M, et al. Retrospective multiiristitutional study of the prevalence or early death in Dravet syndrorne. Epilepsia 2011 ; 52 : 1144-9.
 
5) Okumura A, et al. Acute encephalopathy in children with Dravet syndrome. Epilepsia 2012 ; 53 : 79-86.
PubMed
6) Tian X, et al. The clinical outcome and neuroimaging of acute encephalopathy after Status epilepticus in Dravet syndrome. Dev Med Child Neurol 2018 ; 60 : 566-73.
PubMed
7) Myers KA, et al. Fatal cerebral edema with status epilepticus in children with Dravet syndrome : report of 5 cases. Pediatrics 2017 ; 139 : e20161933.
PubMed
8) Kobayashi K, et al. Genetic seizure susceptibility underlying acute encephalopathies in childhood. Epilepsy Res 2010 ; 91 : 143-52.
PubMed
9) Saitoh M, et al. Mutations of the SCN1A gene in acute encephalopathy. Epilepsia 2012 ; 53 : 558-64.
PubMed
10) Gaily E, et al. Dravet syndrome : new potential genetic modifiers, imaging abnormalities, and ictal findingg., Epilepsia 2013 ; 54 : 1577-85.
PubMed
P.241 掲載の参考文献
1) Minic S, et al. Systematic review or central nervous system anomalies in incontinentia pigmenti. Orphanet J Rare Dis 2013 ; 8 : 25.
 
2) Yang Y, et al. Neonatal incontinentia pigmenti : six cases and a literature review. Exp Ther Med 2014 ; 8 : 1797-806.
 
3) Abe S, et al. Early infantile manifestations of incontinentia pigmenti mimicking acute encephalopathy. Brain Dev 2011 ; 33 : 28-34.
PubMed
4) Kanai S, et al. Late-onset cerebral arteriopathy in a patient with incontinentia pigmenti. Brain Dev 2021 ; 43 : 580-4.
 
5) Ruggieri M, et al. Mosaic neurocutaneous disorders and their causes. Semin Pediatric Neurol 2015 ; 22 : 207-33.
PubMed
6) Merke DP, et al. Congenital adrenal hyperplasia. Lancet 2005 ; 365 : 2125-36.
PubMed
7) Abe Y, et al. Manifestations and characteristics of congenital adrenal hyperplasia-associated encephalopathy. Brain Dev 2016 ; 38 : 638-47.
PubMed
8) 阿部裕一ほか. 先天性副腎皮質過形成に伴う脳症. 小児科学レクチャー 2012 ; 2 : 918-24.
 
9) Hirayama Y, et al. "Symptomatic" infection-associated acute encephalopathy in children with underlying neurological disorders. Brain Dev 2017 ; 39 : 243-7.
PubMed
10) Raymond M, et al. Chronic perinatal hypoxia reduces glutamate-aspartate transporter function in astrocytes through the Janus kinase/signal transducer and activator or transcription pathway. J Neurosci 2011 ; 31 : 17864-71.
PubMed
P.249 掲載の参考文献
1) Mazeraud A, et al. Septic-associated encephalopathy : a comprehensive review. Neurotherapeutics 2020 ; 17 : 392-403.
PubMed
2) Smith HAB, et al. Diagnosing delirium in critically ill children : validity and reliability of the pediatric confusion assessment method for the intensive care unit. Crit Care Med 2011 ; 39 : 150e-7.
 
3) Smith HAB, et al. The Preschool confusion assessment method for the ICU : valid and reliable delirium monitoring for critically ill infants and children. Crit Care Med 2016 ; 44 : 592e-600.
 
4) Igarashi T, et al. Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol 2014 ; 18 : 525-57.
PubMed
5) 高木智恵子ほか. 中枢神経障害-VTEC感染症に見られる重篤中枢神経障害の機序に対する考察-HUS/TTP症候群説? Vero毒素の直接神経細胞障害説? 日本臨床 1997 ; 55 : 731-5.
Medical*Online
6) 柳澤敦広ほか. 溶血性尿毒症症候群に併発した急性壊死壊死脳症. 日児腎誌 2009 ; 22 : 161-5.
 
7) 日本川崎病学会, 日本川崎病研究センター, 厚生労働科学研究 難治性血管炎に関する調査研究班. 川崎病診断の手引き 改訂第6版. 2019年5月. http://www.jskd.jp/info/pdf/tebiki201906.pdf
 
8) Kumrah R, et al. Immunogenetics of Kawasaki disease. Clin Rev Allergy Immunol 2020 ; 59 : 122-39.
PubMed
9) 日本小児循環器学会学術委員会 川崎病急性期治療のガイドライン作成委員会. 川崎病急性期治療のガイドライン (2020年改訂版), 日小循誌 2020 ; 36 (Suppl 1) : s1-29.
 
10) 屋代真弓ほか. 第21回川崎病全国調査成績. 小児科診療 2012 ; 75 : 507-23.
Medical*Online
11) 森秀洋ほか. 可逆性脳梁膨大部病変を有する軽症脳炎・脳症を合併した川崎病に対する血漿交換療法. 日児誌 2020 ; 124 : 1514-9.
 
12) 川合玲子ほか. 川崎病にけいれん・意識障害を合併した4例. 日児誌 2020 ; 124 : 539-44.
 
13) Shiba T, et al. Acute encephalopathy with biphasic seizures and late reduced diffusion in Kawasaki disease. Pediatr Int 2017 ; 59 : 1276-8.
PubMed
14) Shimizu M, et al. Clinical significance or serum soluble TNF receptor II level and soluble TNF receptor II/I ratio as indicators of coronary artery lesion development in Kawasaki disease. Cytokine 2018 ; 108 : 168-72.
 
P.257 掲載の参考文献
1) Dalmau J, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007 ; 61 : 25-36.
PubMed
2) Groc L, et al. NMDA receptor surface mobility depends on NR2A-2B subunits. Proc Natl Acad Sci USA 2006 ; 103 : 18769-74.
PubMed
3) Takahashi Y. Epitope of autoantibodies to N-methyl-D-aspartate receptor heteromers in paraneoplastic limbic encephalitis. Ann Neurol 2008 ; 64 : 110-1.
 
4) Dalmau J, et al. Anti-NMDA-receptor encephalitis : case series and analysis of the effects of antibodies. Lancet Neurol 2008 ; 7 : 1091-8.
PubMed
5) 高橋幸利ほか. 自己免疫性脳炎・脳症の診断・治療の本邦での現状. 脳神経内科 2022 ; 96 : 255-61.
 
6) Granerod J, et al. Causes of encephalitis and differences in their clinical presentations in England : a multicentre, population-based prospective study. Lancet Infect Dis 2010 ; 10 : 835-44.
 
7) 高橋幸利ほか. 神経疾患とNMDA型グルタミン酸受容体抗体. 日児誌 2014 ; 118 : 1695-707.
 
8) Kawano G, et al. Case report : rituximab improved epileptic spasms and EEG abnormalities in an infant with West syndrome and anti-NMDAR encephalitis associated with APECED. Front Neurol 2021 ; 12 : 679164.
 
9) Hughes EG, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010 ; 30 : 5866-75.
PubMed
10) Zhang Q, et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 2012 ; 45 : 610-5.
PubMed
11) Takahashi Y, et al. Characteristics of internalization or NMDA-type GluRs with antibodies to GluN1 and GluN2B. J Neuroimmunol 2020 ; 349 : 577427.
 
12) Takahashi Y, et al. Passive transfer of rabbit antibodies against human NMDA-type GluR into mice : effect of antibodies to GluN1. Clinical and Experimental Neuroimmunology 2016 ; 7 : 381-7.
 
13) 高橋幸利ほか. 神経疾患関連抗体 : NMDA型グルタミン酸受容体抗体 (抗NMDA受容体抗体), 小児内科 2017 ; 49増刊号 : 404-7.
 
14) Dalmau J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists : mechanisms and models. Lancet Neurol 2019 ; 18 : 1045-57.
PubMed
15) Omata T, et al. Ovarian teratoma development after anti-NMDA receptor encephalitis treatment. Brain Dev 2017 ; 39 : 448-51.
PubMed
16) Tituaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study. Lancet Neurol 2013 ; 12 : 157-65.
 
17) 高橋幸利ほか. 非ヘルペス性急性辺縁系脳炎157例の検討 : 急性期治療と予後. Neuroinfection 2016 ; 21 : 121-7
 
P.265 掲載の参考文献
1) Krupp LB, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 2013 ; 19 : 1261-7.
 
2) Yamaguchi Y, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 2016 ; 87 : 2006-15.
PubMed
3) Azumagawa K, et al. A nation-wide survey of Japanese pediatric MOG-antibody-associated diseases. Brain Dev 2021 ; 43 : 705-13.
PubMed
4) Baumann M, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. Neurol Neurosurg Psychiatry 2015 ; 86 : 265-72.
 
5) Takai Y, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease : an immunopathological study. Brain 2020 ; 143 : 1431-46.
PubMed
6) Nishiyama M, et al. Clinical time course of pediatric acute disseminated encephalomyelitis. Brain Dev 2019 ; 41 : 531-7.
PubMed
7) Cole J, et al. Acute disseminated encephalomyelitis in children : an updated review based on current diagnostic criteria. Pediatr Neurol 2019 ; 100 : 26-34.
PubMed
8) Pohl D, et al. Acute disseminated encephalomyelitis. Neurology 2016 ; 87 (Suppl 2) : S38-45.
 
9) Bruijstens AL, et al. E. U. paediatric MOG consortium consensus : Part 5-treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 2020 ; 29 : 41-53.
 
10) Waters P, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMS Neurol 2020 ; 77 : 82-93.
 
11) Baumann M, et al. E. U. paediatric MOG consortium consensus : Part 2-neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody associated disorders. Eur J Paediatr Neurol 2020 ; 29 : 14-21.
 
12) Hennes EM, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017 ; 89 : 900-8.
PubMed
13) Hacohen Y, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018 ; 75 : 478-87.
PubMed
14) Hasegawa S, et al. A nationwide survey or opsoclonus-myoclonus syndrome in Japanese children.Brain Dev 2015 ; 37 : 656-60.
PubMed
15) Brunklaus A, et al. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics 2011 ; 128 : e388-94.
PubMed
16) Rudnick E, et al. Opsoclonus-myoclonus ataxia syndrome in neuroblastoma : clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001 ; 36 : 612-22.
 
17) Pranzatelli MR, et al. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome : a cross-sectional study. Front Neurol 2017 ; 8 : 498.
 
18) Petit-Pedro M, et al. Absence of GluD2 antibodies in patients with opsoclonus-myoclonus syndrome. Neurology 2021 ; 90 : e1082-7.
 
19) Pranzatelli MR, et al. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children. Pediart Blood Cancer 2018 ; 65 : e27097.
 
20) Matthay KK, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 2005 ; 228 : 275-82.
PubMed
21) Sheridan A, et al. IQ predictors in pediatric opsoclonus myoclonus syndrome : a large international cohort study. Dev Med Child Neurol 2020 ; 62 : 1444-9.
PubMed
P.270 掲載の参考文献
1) Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996 ; 334 : 494-500.
 
2) Casey SO, et al. Posterior rcversible encephalopathy syndrome : utility or FLAIR irnaging in the detection of cortical and subcortical lesions. Am J Neuroradiol 2000 ; 21 : 1199-206.
PubMed
3) Bartynski WS, et al. Posterior reversible encephalopathy syndrome after solid organ. AJNR Am J Neuroradiol 2008 ; 29 : 924-30.
PubMed
4) Ishikura K, et al. Posterior reversible encephalopathy syndrome in children with kidney diseases. Pediatr Nephrol 2012 ; 27 : 375-84.
PubMed
5) 伊藤泰広ほか. Reversible posterior leukoencephalopathy syndromeの疾患概念. 神経内科 2005 ; 63 : 307-22.
 
6) Anderson RC, et al. Posterior reversible encephalopathy syndrome (PRES) : pathophysiology and neuro-imaging. Front Neurol 2020 ; 11 : 463.
PubMed
7) Bechstein WO. Neurotoxicity of calcineurin inhibitors : impact and clinical management. Transpl Int 2000 ; 13 : 313-26.
PubMed
8) Fugate JE. Posterior reversible encephalopathy syndrome : clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 2015 ; 14 : 914-25.
PubMed
9) 岡本浩一郎ほか. PRES-posterior reversible encephalopathy syndrome, Brain Nerve 2017 ; 69 : 129-41.
 
10) Bartynski WS, et al. Disttinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007 ; 28 : 1320-7.
PubMed
11) McKinney AM, et al. Central-variant posterior reversible encephalopathy syndrome : brainstem or basal ganglia involvement lacking cortical or subcortical cerebral edema. AJR Am J Roentgenol 2013 ; 201 : 631-8.
 
12) Fischer M, et al. Posterior reversible encephalopathy syndrome. J Neurol 2017 ; 264 : 1608-16.
PubMed
13) Servillo G, et al. Posterior reversible encephalopathy syndrome in intensive care medicine. Intensive Care Med 2007 ; 33 : 230-6.
PubMed
14) 千葉厚郎. Reversible posterior leukoencephalopathy syndromeの薬物療法. 神経内科 2005 ; 63 : 359-63.
 
P.275 掲載の参考文献
1) Davis DP, Marino A. Acute cerebellar ataxia in a Toddler : case report and literature review. J Emerg Med 2003 ; 24 : 281-4.
 
2) Nussinovitch M, et al. Post-infectious acute cerebellar ataxia in children. Clin Pediatr 2003 ; 42 : 581-4.
PubMed
3) van der Maas NAT, et al. Acute cerebellar ataxia in the Netherlands : a study of the association with vaccinations and varicella zoster infection. Vaccine 2009 ; 27 : 1970-3.
PubMed
4) Fritzler MJ, et al. Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia. BMC Pediatr 2003 ; 3 : 11.
PubMed
5) Cimolai N, et al. Anticentriolar autoantibodies in children with central nervous system manifestations of Mycoplasma pneumoniae infection. J Neurol Neurosurg Psychiatry 1994 ; 57 : 638-9.
PubMed
6) Ito H, et al. Antineuronal antibodies in acute cerebellar ataxia following Epstein-Barr virus infection. Neurology 1994 ; 44 : 1506-7.
PubMed
7) Uchibori A, et al. Autoantiobodies in postinfectious acute cerebellar ataxia. Neurology 2005 ; 65 : 1114-6.
 
8) Ishikawa N, et al. Recurrent acute cerebellar ataxia associated with anti-cardiolipin antibodies. Brain Dev 2010 ; 32 : 588-91.
PubMed
9) Connolly AM, et al. Course and outcome of acute cerebellar ataxia. Ann Neurol 1994 ; 35 : 673-9.
PubMed
10) Pavone P, et al. Ataxia in children : early recognition and clinical evaluation. Ital J Pediatr 2017 ; 43 : 6.
PubMed
11) 川上雄平ほか. 99mTC-ethyl cysteinate dimer (ECD) 脳血流single photon emission computer tomography (SPECT) が病勢評価に有用であった急性小脳失調症の1例. 小児内科 2020 ; 52 : 985-8.
Medical*Online
12) Sugiyama N, et al. A prognostic value of neuron-specific enolase in cerebrospinal fluid of acute cerebellar ataxia. Tokai J Exp Clin Med 2010 ; 35 : 25-8.
PubMed

書評

最近チェックした商品履歴

Loading...